What antibiotics should be used to treat carbapenem‑resistant Pseudomonas aeruginosa isolated from broncho‑alveolar lavage in an adult patient with normal renal function?

Treatment of Carbapenem-Resistant Pseudomonas aeruginosa from BAL

For carbapenem-resistant Pseudomonas aeruginosa isolated from bronchoalveolar lavage, use ceftolozane-tazobactam as first-line therapy if the isolate is susceptible in vitro, with consideration of ceftazidime-avibactam, imipenem-relebactam, or cefiderocol as alternatives based on susceptibility testing. 1

Treatment Algorithm Based on Clinical Severity

For Patients NOT in Septic Shock or High Risk of Death (mortality <15%)

• Use monotherapy with a single antibiotic to which the isolate is susceptible 2
• Preferred agents (in order):
  • Ceftolozane-tazobactam (strongest recommendation for difficult-to-treat resistant P. aeruginosa) 1
  • Ceftazidime-avibactam (if susceptible)
  • Imipenem-relebactam (if susceptible)
  • Cefiderocol (particularly for metallo-β-lactamase producers) 3, 4

For Patients in Septic Shock or High Risk of Death (mortality >25%)

• Use combination therapy with 2 antibiotics to which the isolate is susceptible 2
• When only polymyxins, aminoglycosides, or fosfomycin are active: use two in vitro active drugs in combination 1
• Discontinue combination therapy once septic shock resolves 2

Critical Pitfalls to Avoid

Never use aminoglycoside monotherapy - this is strongly contraindicated regardless of susceptibility 2. Aminoglycosides may only be used as part of combination therapy.

Adjunctive Inhaled Therapy

For ventilator-associated pneumonia when the organism is susceptible only to polymyxins or aminoglycosides:

• Add inhaled colistin to systemic therapy 2
• Consider adjunctive inhaled antibiotics as last resort for patients failing IV therapy alone 2

Dosing Optimization

Use pharmacokinetic/pharmacodynamic-optimized dosing rather than standard manufacturer recommendations 2. This includes:

• Extended or continuous infusions of beta-lactams
• Weight-based dosing
• Therapeutic drug monitoring when available

Duration of Therapy

Treat for 7 days in most cases of hospital-acquired or ventilator-associated pneumonia 2. Adjust duration based on clinical, radiologic, and laboratory response.

Evidence Quality and Nuances

The 2016 IDSA/ATS guidelines [2-2 provide the foundational framework but predate newer agents. The 2022 ESCMID guidelines 1 offer more recent guidance specifically addressing carbapenem-resistant organisms and recommend ceftolozane-tazobactam for severe difficult-to-treat resistant P. aeruginosa infections, though they acknowledge the evidence is very low quality. Recent data 3 supports newer beta-lactam/beta-lactamase inhibitor combinations and cefiderocol as preferred over polymyxin-based regimens due to superior cure rates and reduced nephrotoxicity.

The key clinical decision point is patient severity: stable patients receive monotherapy guided by susceptibility testing, while critically ill patients in septic shock require combination therapy until stabilized. This approach balances mortality reduction against antibiotic stewardship and toxicity concerns.

For organisms with metallo-β-lactamase production, cefiderocol demonstrates unique stability and maintains activity through its iron-dependent uptake mechanism that bypasses typical resistance mechanisms 4. When newer agents are unavailable and only older antibiotics show activity, combination therapy is preferred over monotherapy to improve outcomes 1, 5.